stockrow
Friday 6 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.72
1.70
+8.49%
Follow REPL
Alert me
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
11.29 | 12.53 | 14.26 | 14.68 | 33.25 | 19.46 | 17.52 | 10.72 | 7.95 | 4.79 |
Net Debt/EBITDA |
2.16 | 3.20 | 3.94 | 2.36 | 5.87 | 3.26 | 2.94 | 1.44 | 1.55 | 0.51 |
Debt/Assets |
0.00% | 0.00% | 4.25% | 14.85% | 4.56% | 5.29% | 8.14% | 13.99% | 12.53% | 31.65% |
Debt/Equity |
0.00 | 0.00 | 0.05 | 0.19 | 0.05 | 0.06 | 0.09 | 0.18 | 0.17 | 0.63 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.92 | 0.81 | 0.82 | 1.15 | 0.76 | 0.70 | 0.73 | 0.86 | 0.78 | 0.89 |
Capex/Depreciation |
(1.95) | 9.71 | 1.66 | 15.87 | (0.77) | (0.53) | 0.71 | 0.59 | 1.23 | (5.37) |
Interest Coverage |
(385.88) | (66.77) | (11.97) | (29.28) | (26.13) | (53.22) | (42.57) | (35.25) | (33.15) | (36.11) |
| 38.93% | 99.55% | (56.17%) | (32.73%) | (23.70%) | (25.94%) | (36.06%) | (46.42%) | (62.58%) | (107.88%) | |
| (17.52%) | (44.79%) | (28.10%) | (27.10%) | (20.81%) | (23.51%) | (31.47%) | (38.05%) | (47.60%) | (71.05%) | |
ROIC |
0.00% | 0.00% | (201.35%) | (70.34%) | (105.94%) | (184.96%) | (451.38%) | (665.18%) | (14,280.95%) | (8,036.55%) |
Return on Tangible Assets |
(37.11%) | (32.89%) | (21.52%) | (31.10%) | (16.97%) | (30.18%) | (30.78%) | (53.45%) | (55.29%) | (134.24%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.47) | (3.24) | (1.21) | (1.96) | (1.38) | (1.62) | (2.24) | (2.87) | (2.47) | (3.07) |
Cash per Share |
4.14 | 12.36 | 5.81 | 4.92 | 10.30 | 7.58 | 10.02 | 6.32 | 6.01 | 2.90 |
Shareholders Equity per Share |
(2.32) | (5.64) | 5.94 | 5.36 | 10.78 | 7.88 | 9.54 | 5.63 | 5.16 | 1.79 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.32) | (5.64) | 5.94 | 5.36 | 10.78 | 7.88 | 9.54 | 5.63 | 5.16 | 1.79 |
Free Cash Flow |
(7.31) | (16.15) | (27.98) | (67.09) | (63.78) | (84.52) | (130.32) | (191.13) | (198.94) | (284.57) |
Working Capital |
20.42 | 59.54 | 131.10 | 162.38 | 469.20 | 383.22 | 558.78 | 393.23 | 433.52 | 220.89 |
Capital Expenditures |
(0.24) | (0.14) | (2.60) | (6.54) | (2.39) | (2.34) | (2.27) | (5.66) | (6.69) | (4.22) |
Net Current Asset Value |
(11.93) | (28.52) | 124.51 | 123.87 | 439.38 | 354.01 | 501.30 | 320.45 | 360.40 | 112.89 |
| Other line items | ||||||||||
Quick Ratio |
11.08 | 12.38 | 13.89 | 14.44 | 32.95 | 19.21 | 17.33 | 10.52 | 7.82 | 4.65 |
Depreciation/Fixed assets |
0.36 | (0.04) | (0.13) | (0.06) | 0.41 | 0.55 | (0.43) | (0.92) | (0.40) | 0.06 |
Cash ROIC |
(80.57%) | (48.23%) | (10.02%) | (17.33%) | (6.38%) | (10.17%) | (10.94%) | (22.14%) | (20.54%) | (52.67%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.42) | (3.22) | (1.09) | (1.77) | (1.33) | (1.57) | (2.20) | (2.79) | (2.39) | (3.02) |
Capex per Share |
(0.05) | (0.03) | (0.11) | (0.19) | (0.05) | (0.04) | (0.04) | (0.09) | (0.08) | (0.05) |
Average Receivables |
1.90 | 1.90 | 2.43 | 2.72 | 2.96 | 3.00 | 3.00 | 3.93 | 4.32 | 2.67 |
Average Payables |
1.16 | 1.16 | 4.54 | 5.26 | 2.89 | 3.04 | 4.55 | 3.97 | 7.52 | 9.57 |
Average Assets |
43.99 | 43.99 | 109.74 | 194.21 | 388.60 | 502.15 | 553.89 | 567.16 | 519.53 | 441.86 |
Average Common Equity |
(19.79) | (19.79) | 54.89 | 160.79 | 341.22 | 454.98 | 483.26 | 464.90 | 395.18 | 291.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026